Audax Therapeutics

Audax Therapeutics is a preclinical-stage biotechnology company dedicated to developing regenerative therapies for diabetes. Spun out from Helmholtz Munich, the company focuses on the discovery and development of novel agents that inhibit the insulin inhibitory receptor (Inceptor), a key regulator of beta cell mass and function. By blocking Inceptor, Audax aims to sensitize the insulin signaling pathway and trigger the regeneration of insulin-producing beta cells, potentially offering a disease-modifying treatment for both Type 1 and Type 2 diabetes. The company's approach represents a paradigm shift from managing symptoms to reversing the underlying loss of functional beta cell mass.